28 November 2023: Original Paper
Toll-Like Receptor 3 mRNA Expression of Peripheral Blood Mononuclear Cells Identifies Kidney Recipients with Potential for Improved Graft Performance
Sławomir C. Zmonarski 1ACDE* , Mirosław Banasik 1D , Marcelina Żabińska 1AB , Tomasz Gołębiowski 1BD , Joanna M. Zmonarska 2BF , Magdalena Krajewska 1FGDOI: 10.12659/AOT.941266
Ann Transplant 2023; 28:e941266
Table 2 Comparison of unrelated continuous variables.
| Parameter | Group | Median | Q25–Q75 | p= |
|---|---|---|---|---|
| All patients | eGFR 0–30 | −1.67 | −2.68–0.03 | 0.072 |
| Baseline TLR3-mRNA (ΔΔCt) | eGFR >60 | −0.40 | −1.69–0.84 | |
| All patients | eGFR 0–30 | −1.67 | −2.68–0.03 | 0.011 |
| Baseline TLR3-mRNA (ΔΔCt) | eGFR 46–60 | −0.42 | −1.19–0.21 | |
| All patients | eGFR 0–30 | −1.67 | −2.68–0.03 | 0.004 |
| Baseline TLR3-mRNA (ΔΔCt) | eGFR 31–45 | −0.28 | −0.96–1.76 | |
| All patients | UCF | 14.98 | 8.51–30.46 | 0.55 |
| Follow-up time (months) | FCF | 11.4 | 7.82–35.78 | |
| All patients | UCF | −1.044 | −1.78–−0.172 | 0.005 |
| Baseline TLR3-mRNA | FCF | −0.253 | −1.05–0.73 | |
| All patients | UCF | 51 | 38–64 | 0.15 |
| Baseline eGFR (ml/min) | FCF | 46 | 37–57 | |
| All patients | UCF | 0.76 | −7.33–8.68 | 0.053 |
| Donor-recipient age (y) | FCF | −4.99 | −15.6–4.13 | |
| All patients | UCF | 0.041 | 0.03–0.08 | 0.043 |
| Baseline tacrolimus (mg/kg) | FCF | 0.063 | 0.04–0.11 | |
| All patients | Low-TLR3-mRNA | 45 | 30–60 | 0.057 |
| Follow-up: eGFR (ml/min) | High-TLR3-mRNA | 52 | 41–64 | |
| Cohort: Baseline eGFR >60 (ml/min) | UCF | −1.11 | −2.25–−0.067 | 0.027 |
| Baseline TLR3-mRNA (ΔΔCt) | FCF | 0.75 | −0.43–1.15 | |
| ΔΔCt – the measure of the expression of Toll-like receptors (see “Method”); eGFR – estimated glomerular filtration rate (ml/min); FCF – favorable course of follow-up; Q25–Q75: margins of lower and upper quartiles; TLR3-mRNA – expression of messenger RNA of Toll-like receptor 3 (Low – mRNA expression below the median for the general cohort of patients; High – mRNA expression over the median for the general cohort of patients); UCF – unfavorable course of follow-up; (y) – years. | ||||